COVID-19 changed the world seemingly overnight. We went from “business as usual” to the “new normal” at warp speed. The impact of the pandemic will be felt by businesses across the globe for years to come. One of the industries experiencing the greatest impact is Life Sciences, particularly in the area of clinical trials.
In light of the “new normal,” the life sciences industry must pivot, transitioning from its traditional operating model to an accelerated, technology-enabled paradigm for drug development, clinical trials and regulatory approvals. To do that, the industry must leverage modern digital sciences and technologies to accelerate the development of new therapies and bring new, potentially lifesaving treatments to market in record time.
When it comes to clinical trials, one thing has become abundantly clear in light of the COVID-19 pandemic – the traditional process of face-to-face visits and on-site monitoring needs to be re-examined. Widespread travel bans and health and safety guidelines such as social distancing forced sponsors to find new ways to collaborate with trial sites.
With increasing pressure to accelerate drug development, enhance collaboration and reduce costs despite the challenges brought forth by the pandemic, many sponsors turned to the Cognizant Shared Investigator Platform (SIP), a robust tool that unites sponsors and clinical researchers.
SIP transforms how sponsors and sites collaborate throughout the clinical trial lifecycle, providing a solution for streamlining clinical trial set up and execution, and resulting in improved investigator experiences and increased collaboration across the clinical ecosystem.
The adoption of digital work practices like those provided by the SIP platform enables life science companies to adapt in the face of current challenges and not only sustain, but accelerate, clinical trials. This move to modern trial technologies is transforming the industry, turning a disruption into a change for the better.